PF-0477736 ≥95%

Supplier: ADIPOGEN CORP MS

Synonyms: PF-0477736, (R)-α-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-cyclohexaneacetamide

SYN-1174-M001 SYN-1174-M005 SYN-1174-M010 SYN-1174-M050
102992-556EA 96.92 USD
102992-556 102992-558 102992-560 102992-562
PF-0477736 ≥95%
PF-477736

Antagonizing the Chk1-mediated cell cycle checkpoints has emerged as an attractive target for anticancer therapy. If Chk1 activity is blocked, DNA-damaged or spindle-disrupted cells would exit cell cycle arrest before full repair and subsequently undergo mitotic catastrophe or cell death. Chk1 inhibitors consequently increase the therapeutic index of DNA-damaging or antimitotic agents as well. PF-0477736 is a selective, potent ATP-competitive Chk1 inhibitor, derived from PF-0394691, inhibits Chk1 (Ki, 0.49nM) and Chk2 (Ki, 47nM) in vitro. In tests, PF-0477736 was identified as a potent, selective ATP-competitive small-molecule inhibitor that inhibits Chk1 with a Ki of 0.49nM. PF-0477736 abrogates cell cycle arrest induced by DNA damage and enhances cytotoxicity of clinically important chemotherapeutic agents, including gemcitabine and carboplatin. In xenografts, PF-0477736 enhanced the antitumor activity of gemcitabine in a dose-dependent manner. PF-0477736 combinations were well tolerated with no exacerbation of side effects commonly associated with cytotoxic agents.

Formula: C₂₂H₂₅N₇O₂
MW: 419.48 g/mol
Storage Temperature: Freezer
MDL Number: MFCD16038847
CAS Number: 952021-60-2

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR